[Treatment of psoriasis: before and now].

Lakartidningen

Karolinska Universitetssjukhuset - Hudkliniken Stockholm, Sweden Karolinska Universitetssjukhuset - Hudkliniken Stockholm, Sweden.

Published: November 2017

AI Article Synopsis

  • Psoriasis is a common inflammatory skin disease that is often underdiagnosed and undertreated, impacting patients’ quality of life.
  • Recent advancements in treatment have significantly improved management options.
  • Effective management requires a personalized approach, considering disease severity, patient preferences, and effective communication with healthcare providers.

Article Abstract

Treatment of psoriasis: before and now  Psoriasis is a multisystem inflammatory disease primarily affecting the skin. Despite its prevalence and considerable effect on quality of life, psoriasis is still underdiagnosed and undertreated. Many patients seek initial evaluation and treatment at primary care level and therefore it is important to know that treatment of psoriasis has advanced tremendously in recent years. Decisions on psoriasis management should be based on assessment of disease severity and phenotype, the existence of physical and psychological comorbidities, the need for referral to dermatologist for specialist care, the patient's preferences and, when possible, identification and elimination of psoriasis trigger factors. Individual treatment goals should be agreed with the patient and treatment should aim to achieve these goals. An individualized, patient centered approach based on the potential of current treatments and a good interpersonal communication between patient and doctor, is essential for effective management of psoriasis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

treatment psoriasis
8
psoriasis
7
treatment
5
[treatment psoriasis
4
psoriasis now]
4
now] treatment
4
psoriasis now 
4
now  psoriasis
4
psoriasis multisystem
4
multisystem inflammatory
4

Similar Publications

Multiple parameters define the treatment course with biologics for a psoriatic patient while treatment switches are often associated with worse prognosis. The purpose of this study was to describe the switching patterns of biologics for psoriasis in the Greek market landscape and to detect associated factors that may impact the evolvement of selected therapy. This is a retrospective cohort study using data recorded in the nationwide digital prescription database of Greece.

View Article and Find Full Text PDF

Introduction: Psoriasis (PsO) is a common chronic, inflammatory, immune-mediated disease. In 2023, a 4.4% prevalence of PsO was reported in Portugal.

View Article and Find Full Text PDF

Objective: To characterize the systemic treatment patterns and current state of moderate-to-severe psoriasis patients in real-world settings in Greece.

Methods: CRYSTAL-Greece was a multicenter, cross-sectional and retrospective chart review study assessing Psoriasis Area and Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5-Dimensions 5-Levels (EQ-5D-5L). Eligible patients were consented adults (18-75 years old) on continuous treatment with any approved systemic therapy regimen for ≥24 weeks.

View Article and Find Full Text PDF

Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated. We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis.

View Article and Find Full Text PDF

The rising incidence of skin disorders has necessitated the exploration of innovative therapeutic modalities that harness the beneficial properties of natural compounds. Phytoconstituents, renowned for their diverse pharmacological attributes, present considerable promise in the management of various dermatological conditions. This review delineates the integration of phytoconstituents into ethosomal formulations, which are advanced lipid-based carriers specifically designed to enhance transdermal delivery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!